324 related articles for article (PubMed ID: 18021082)
1. Overview of monoclonal gammopathies of undetermined significance.
Vogt RF; Marti GE
Br J Haematol; 2007 Dec; 139(5):687-9. PubMed ID: 18021082
[TBL] [Abstract][Full Text] [Related]
2. Waldenström macroglobulinaemia and IgM monoclonal gammopathy of undetermined significance: emerging understanding of a potential precursor condition.
McMaster ML; Caporaso N
Br J Haematol; 2007 Dec; 139(5):663-71. PubMed ID: 18021080
[TBL] [Abstract][Full Text] [Related]
3. Multiple myeloma, chronic lymphocytic leukaemia and associated precursor diseases.
Landgren O; Kyle RA
Br J Haematol; 2007 Dec; 139(5):717-23. PubMed ID: 18021086
[TBL] [Abstract][Full Text] [Related]
4. [Monoclonal gammopathies of undetermined significance called "MGUS"].
Clément F
Schweiz Med Wochenschr; 1989 Jul; 119(27-28):970-8. PubMed ID: 2508215
[TBL] [Abstract][Full Text] [Related]
5. [Monoclonal gammopathy of undetermined significance].
Chaïbi P; Merlin L; Thomas C; Piette F
Ann Med Interne (Paris); 2002 Nov; 153(7):459-66. PubMed ID: 12598832
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal gammopathies of undetermined significance.
Kyle RA; Rajkumar SV
Best Pract Res Clin Haematol; 2005; 18(4):689-707. PubMed ID: 16026745
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.
Kyle RA; Rajkumar SV
Br J Haematol; 2007 Dec; 139(5):730-43. PubMed ID: 18021088
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
[TBL] [Abstract][Full Text] [Related]
9. A long-term study of prognosis in monoclonal gammopathy of undetermined significance.
Kyle RA; Therneau TM; Rajkumar SV; Offord JR; Larson DR; Plevak MF; Melton LJ
N Engl J Med; 2002 Feb; 346(8):564-9. PubMed ID: 11856795
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
Viera S; Ludek P; Zdeněk A; Marta K; Martin Š; Sabina Š; Zdeněk K
Klin Onkol; 2018; 31(4):270-276. PubMed ID: 30541309
[TBL] [Abstract][Full Text] [Related]
11. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS).
Bird J; Behrens J; Westin J; Turesson I; Drayson M; Beetham R; D'Sa S; Soutar R; Waage A; Gulbrandsen N; Gregersen H; Low E;
Br J Haematol; 2009 Oct; 147(1):22-42. PubMed ID: 19673884
[No Abstract] [Full Text] [Related]
12. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance.
Kyle RA; Therneau TM; Rajkumar SV; Offord JR; Larson DR; Plevak MF; Melton LJ
Semin Oncol; 2003 Apr; 30(2):169-71. PubMed ID: 12720130
[TBL] [Abstract][Full Text] [Related]
13. [Monoclonal gammopathies of undetermined significance].
Krizalkovicová V; Maisnar V; Pour L; Radocha J; Hájek R
Klin Onkol; 2008; 21(4):160-4. PubMed ID: 19102222
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and IgM-related disorders.
Morra E; Cesana C; Klersy C; Barbarano L; Varettoni M; Cavanna L; Canesi B; Tresoldi E; Miqueleiz S; Bernuzzi P; Nosari AM; Lazzarino M
Leukemia; 2004 Sep; 18(9):1512-7. PubMed ID: 15322559
[TBL] [Abstract][Full Text] [Related]
15. Familial monoclonal gammopathy: hyper-responsive B cells in unaffected family members.
Steingrímsdóttir H; Einarsdóttir HK; Haraldsdóttir V; Ogmundsdóttir HM
Eur J Haematol; 2011 May; 86(5):396-404. PubMed ID: 21342269
[TBL] [Abstract][Full Text] [Related]
16. Clinical practice. Monoclonal gammopathy of undetermined significance.
Bladé J
N Engl J Med; 2006 Dec; 355(26):2765-70. PubMed ID: 17192542
[No Abstract] [Full Text] [Related]
17. Predictive variables for malignant transformation in 452 patients with asymptomatic IgM monoclonal gammopathy.
Morra E; Cesana C; Klersy C; Varettoni M; Cavanna L; Canesi B; Tresoldi E; Barbarano L; Lazzarino M;
Semin Oncol; 2003 Apr; 30(2):172-7. PubMed ID: 12720131
[TBL] [Abstract][Full Text] [Related]
18. Czech Registry of Monoclonal Gammopathies - Technical Solution, Data Collection and Visualisation.
Brozova L; Schwarz D; Snabl I; Kalina J; Pavlickova B; Komenda M; Jarkovský J; Němec P; Horinek D; Stefanikova Z; Pour L; Hájek R; Maisnar V
Klin Onkol; 2017; 30(Supplementum2):43-50. PubMed ID: 28903570
[TBL] [Abstract][Full Text] [Related]
19. Secondary malignancies in patients with multiple myeloma, Waldenström macroglobulinemia and monoclonal gammopathy of undetermined significance.
Castillo JJ; Gertz MA
Leuk Lymphoma; 2017 Apr; 58(4):773-780. PubMed ID: 27546465
[TBL] [Abstract][Full Text] [Related]
20. A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders.
Varettoni M; Zibellini S; Boveri E; Klersy C; Candido C; Rattotti S; Ferretti VV; Defrancesco I; Mangiacavalli S; Nizzoli ME; Flospergher E; Zerbi C; Bergamini F; Benvenuti P; Brociner M; Merati G; Paulli M; Arcaini L
Br J Haematol; 2019 Nov; 187(4):441-446. PubMed ID: 31276195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
